Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy and safety results from a phase 2, open-label study

Young-Suk Lim; Chun-Yen Lin; Jeong Heo; Ho Bae; Wan-Long Chuang; Tak Yin Owen Tsang; Claire Fournier; Aric Josun Hui; Trinh Huy; Susanna Tan; Yang Zhao; John F. Flaherty; Vithika Suri; Anuj Gaggar; Diana Brainard; Stephen Ryder; Harry L. A. Janssen

Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy and safety results from a phase 2, open-label study

Young-Suk Lim, Chun-Yen Lin, Jeong Heo, Ho Bae, Wan-Long Chuang, Tak Yin Owen Tsang, Claire Fournier, Aric Josun Hui, Trinh Huy, Susanna Tan, Yang Zhao, John F. Flaherty, Vithika Suri, Anuj Gaggar, Diana Brainard, Stephen Ryder, Harry L. A. Janssen

School of Medicine

Research output: Contribution to journal › Journal Article › peer-review

Original language	American English
Journal	Journal of Hepatology
Volume	75
State	Published - 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Lim, Y.-S., Lin, C.-Y., Heo, J., Bae, H., Chuang, W.-L., Tsang, T. Y. O., Fournier, C., Hui, A. J., Huy, T., Tan, S., Zhao, Y., Flaherty, J. F., Suri, V., Gaggar, A., Brainard, D., Ryder, S., & Janssen, H. L. A. (2021). Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy and safety results from a phase 2, open-label study. Journal of Hepatology, 75.

@article{06f1738bfbd6427687beac1d2036ee92,

title = "Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy and safety results from a phase 2, open-label study",

author = "Young-Suk Lim and Chun-Yen Lin and Jeong Heo and Ho Bae and Wan-Long Chuang and Tsang, {Tak Yin Owen} and Claire Fournier and Hui, {Aric Josun} and Trinh Huy and Susanna Tan and Yang Zhao and Flaherty, {John F.} and Vithika Suri and Anuj Gaggar and Diana Brainard and Stephen Ryder and Janssen, {Harry L. A.}",

year = "2021",

language = "American English",

volume = "75",

journal = "Journal of Hepatology",

issn = "0168-8278",

publisher = "Elsevier B.V.",

}

Lim, Y-S, Lin, C-Y, Heo, J, Bae, H, Chuang, W-L, Tsang, TYO, Fournier, C, Hui, AJ, Huy, T, Tan, S, Zhao, Y, Flaherty, JF, Suri, V, Gaggar, A, Brainard, D, Ryder, S & Janssen, HLA 2021, 'Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy and safety results from a phase 2, open-label study', Journal of Hepatology, vol. 75.

Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy and safety results from a phase 2, open-label study. / Lim, Young-Suk; Lin, Chun-Yen; Heo, Jeong et al.
In: Journal of Hepatology, Vol. 75, 2021.

Research output: Contribution to journal › Journal Article › peer-review

TY - JOUR

T1 - Switching from tenofovir disoproxil fumarate and/or other oral antivirals to tenofovir alafenamide in virally suppressed chronic hepatitis B patients with hepatic impairment: final 2 year efficacy and safety results from a phase 2, open-label study

AU - Lim, Young-Suk

AU - Lin, Chun-Yen

AU - Heo, Jeong

AU - Bae, Ho

AU - Chuang, Wan-Long

AU - Tsang, Tak Yin Owen

AU - Fournier, Claire

AU - Hui, Aric Josun

AU - Huy, Trinh

AU - Tan, Susanna

AU - Zhao, Yang

AU - Flaherty, John F.

AU - Suri, Vithika

AU - Gaggar, Anuj

AU - Brainard, Diana

AU - Ryder, Stephen

AU - Janssen, Harry L. A.

PY - 2021

Y1 - 2021

M3 - Journal Article

SN - 0168-8278

VL - 75

JO - Journal of Hepatology

JF - Journal of Hepatology

ER -